Skip to main content

Peer Review reports

From: Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis

Original Submission
10 Jul 2024 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
23 Jul 2024 Author responded Author comments - Changqing Yu
Resubmission - Version 3
23 Jul 2024 Submitted Manuscript version 3
7 Aug 2024 Reviewed Reviewer Report
8 Aug 2024 Reviewed Reviewer Report - Yavuz Karabag
12 Aug 2024 Author responded Author comments - Changqing Yu
Resubmission - Version 4
12 Aug 2024 Submitted Manuscript version 4
19 Aug 2024 Reviewed Reviewer Report - Yavuz Karabag
1 Sep 2024 Reviewed Reviewer Report
11 Sep 2024 Author responded Author comments - Changqing Yu
Resubmission - Version 5
11 Sep 2024 Submitted Manuscript version 5
18 Sep 2024 Author responded Author comments - Changqing Yu
Resubmission - Version 6
18 Sep 2024 Submitted Manuscript version 6
2 Oct 2024 Reviewed Reviewer Report
3 Oct 2024 Reviewed Reviewer Report
3 Oct 2024 Reviewed Reviewer Report - Yavuz Karabag
6 Oct 2024 Reviewed Reviewer Report - Kwadwo Osei Bonsu
9 Oct 2024 Author responded Author comments - Changqing Yu
Resubmission - Version 7
9 Oct 2024 Submitted Manuscript version 7
24 Oct 2024 Author responded Author comments - Changqing Yu
Resubmission - Version 8
24 Oct 2024 Submitted Manuscript version 8
26 Oct 2024 Author responded Author comments - Changqing Yu
Resubmission - Version 9
26 Oct 2024 Submitted Manuscript version 9
30 Oct 2024 Reviewed Reviewer Report - Yavuz Karabag
31 Oct 2024 Reviewed Reviewer Report
Resubmission - Version 10
Submitted Manuscript version 10
Publishing
4 Nov 2024 Editorially accepted
22 Nov 2024 Article published 10.1186/s12872-024-04316-w

You can find further information about peer review here.

Back to article page